Back to top

Analyst Blog

Zacks Equity Research

FDA Clears Varian's Radiotherapy Software


 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Varian Medical Systems (VAR - Analyst Report) revealed that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RapidPlan knowledge-based software. The software helps automate an important part of the treatment planning process, thereby improving the quality and efficiency of care.

RapidPlan has been showcased at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Atlanta in September. It provides standard of care models to clinicians to use as a baseline for formulating complex intensity-modulated radiotherapy (IMRT) treatment plans for their patients.

RapidPlan helps users to gain knowledge derived from historical treatment plans. It also serves as a learning tool as clinicians can add their best treatment plans to the system and create a new and improved treatment practice model. This model can be shared among other clinicians within a network and create a standard of practice.

Similar products offered by VAR include the RapidArc technology and the Smart Segmentation knowledge-based tool. Based on the cost effectiveness of the new softwares, management plans to create more knowledge-driven solutions for the entire oncology continuum.

Varian is poised to increase its global market share in the radiation oncology market as international markets are still under-equipped to address the growing incidence of cancer. However, the oncology business in North America is witnessing a drop in capital expenditure on account of uncertainty emanating from health care reform and anticipated changes in reimbursement.

VAR currently retains a Zacks Rank #4 (Sell). While we prefer to avoid the stock, other stocks from the medical instruments industry that are worth a look include Mindray Medical International Limited (MR - Analyst Report), with a Zacks Rank #1 (Strong Buy), and Cepheid (CPHD - Analyst Report) and MAKO Surgical Corp. , both with a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%